Research Team
Nitzan Arad, LLM
Contact
Degrees
LLB, Hebrew University of Jerusalem
LLM, Duke University School of Law
Nitzan Arad is an Assistant Research Director with the Duke-Margolis Institute for Health Policy. Her work focuses on drug pricing and payment reforms in Medicare and Medicaid, the legal barriers to value-based payment arrangements for medical products and population-based payment models.
Before joining Duke-Margolis, she was a Director of Public Policy at Teva Pharmaceuticals, where she led research and analysis on a variety of government pricing and reimbursement, intellectual property, trade policy and biosimilar issues, in the U.S. and in international markets. She also interacted regularly with different industry associations and developed policy strategies to support company advocacy efforts on various topics.
Policy Brief
Alzheimer’s Disease Monoclonal Antibodies with Traditional Approval: Clarifying the Pathway for Medicare Postmarket Evidence Development and Use
Nitzan Arad, Elizabeth Staton, Marianne Hamilton Lopez, Mark McClellan
2023
Read MoreComment Letter
Comment Letter to CMS on IRA Price Negotiation Initial Guidance
Mark McClellan, Nitzan Arad, Rachele Hendricks-Sturrup, Marianne Hamilton Lopez
2023
Read MorePolicy Brief
Realizing the Benefits of Biosimilars: Overcoming Rebate Walls
Nitzan Arad, Elizabeth Staton, Marianne Hamilton Lopez, Samson Goriola, Aparna Higgins, Mark McClellan, Barak Richman
2022
Read MoreComment Letter
CMS Comment Letter on Proposed Coverage Decision
Mark McClellan, Beena Bhuiyan Khan, Nitzan Arad, Hannah Graunke, Elizabeth Staton, Marianne Hamilton Lopez
2022
Read MorePolicy Brief
Medicare Coverage of Monoclonal Antibody Treatments for Alzheimer’s Disease: Key Issues from the CMS Proposed Coverage Decision
Nitzan Arad, Beena Bhuiyan Khan, Elizabeth Staton, Hannah Graunke, Marianne Hamilton Lopez, Mark McClellan
2022
Read MorePolicy Brief
Originator Biologics and Biosimilars: Payment Policy Solutions to Increase Price Competition While Maintaining Market Sustainability in Medicare Part B
Nitzan Arad, Derick Rapista, Marianne Hamilton Lopez, Mark McClellan
2021
Read MoreComment Letter
CMS Comment Letter on Medicaid Drug Rebate program
Mark McClellan, Nitzan Arad, Beena Bhuiyan Khan, Nicholas Fiore, Marianne Hamilton Lopez
2021
Read MoreComment Letter
Health Innovation Caucus Comment Letter on Request for Information
Mark McClellan, Marta Wosinska, Nitzan Arad, Rachel Roiland, Alec Lintz, Marianne Hamilton Lopez, Robert S. Saunders
2021
Read MoreProject Report
Monoclonal Antibody Therapies for COVID-19: Recommendation Summary
Duke-Margolis Center for Health Policy
2020
Read MoreWhite Paper
Letter
CMS Comment Letter on Value-Based Purchasing
Mark McClellan, Marta Wosinska, Beena Bhuiyan Khan, Nitzan Arad, Nicholas Fiore, Aparna Higgins, Marianne Hamilton Lopez
2020
Read MoreComment Letter
HHS Comment Letter on Self-Referral Regulations and Anti-Kickback Statute
Mark McClellan, Nitzan Arad, Rachel Roiland, Karley Whelan, Marianne Hamilton Lopez, Robert S. Saunders
2019
Read MoreComment Letter
HHS Comment Letter on Proposed Rebate Rule
Mark McClellan, Gregory Daniel, Nitzan Arad, Nicholas Fiore, Thomas Barker, Susan Dentzer, Christian Springer, Marianne Hamilton Lopez
2019
Read More